We will address the biology of ErbB signaling in cancer and cardiac cells, the regulatory aspects and clinical benefits of NRG-1/ErbB signaling activation in heart failure, and the working mechanisms of different anti-ErbB2 drugs and their degree of cardiotoxicity. This evidence concerns the gene ERBB2 and heart failure.